Skip to main content

16.12.2015 | Original Article | Ausgabe 10/2016

Heart and Vessels 10/2016

Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure

Heart and Vessels > Ausgabe 10/2016
Ryuichi Matsukawa, Toru Kubota, Masanori Okabe, Yusuke Yamamoto
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00380-015-0780-z) contains supplementary material, which is available to authorized users.


Tolvaptan is an oral antagonist of arginine vasopressin receptor 2 that has been approved in Japan to reduce congestive symptoms in patients with heart failure refractory to loop diuretics. However, it is unknown whether the early use of tolvaptan results in better clinical outcomes. We retrospectively analyzed 102 consecutive patients with decompensated heart failure treated with tolvaptan at our hospital. A given patient was defined as a responder when the maximum urine volume was greater than 150 % of that observed before tolvaptan use. A logistic regression analysis revealed that the early use of tolvaptan (within 3 days after admission) was an independent factor associated with tolvaptan responsiveness. There were no significant differences in the baseline clinical parameters between the early and late tolvaptan use groups. However, the early use of tolvaptan was associated with higher tolvaptan responsiveness, a shorter duration of carperitide infusion, earlier initiation of ambulatory cardiac rehabilitation, shorter hospital stay, lower rate of in-hospital death. The early use of tolvaptan was associated with a shorter hospital stay and reduced mortality in our retrospective cohort. It might therefore be beneficial to consider administering tolvaptan earlier in patients with heart failure.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt bestellen und im ersten Jahr 100€ sparen!Jetzt e.Med zum Sonderpreis bestellen!

Supplementary material 1 (DOCX 25 kb)
Supplementary material 2 (JPEG 61 kb)
Supplementary material 3 (JPEG 76 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 10/2016

Heart and Vessels 10/2016 Zur Ausgabe


Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.